|
FR2686899B1
(fr)
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
|
US20050287153A1
(en)
|
2002-06-28 |
2005-12-29 |
Genentech, Inc. |
Serum albumin binding peptides for tumor targeting
|
|
PT1309726E
(pt)
|
2000-03-30 |
2010-03-08 |
Whitehead Biomedical Inst |
Mediadores de interferência por rna específicos de sequência de rna
|
|
US7176278B2
(en)
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
|
US7696320B2
(en)
|
2004-08-24 |
2010-04-13 |
Domantis Limited |
Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
|
|
ES2655912T3
(es)
|
2002-11-08 |
2018-02-22 |
Ablynx N.V. |
Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
|
|
ES2567634T3
(es)
|
2004-02-09 |
2016-04-25 |
Human Genome Sciences, Inc. |
Proteínas de fusión de albúmina
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
US20070269422A1
(en)
|
2006-05-17 |
2007-11-22 |
Ablynx N.V. |
Serum albumin binding proteins with long half-lives
|
|
WO2008012629A2
(en)
|
2006-07-24 |
2008-01-31 |
Biorexis Pharmaceutical Corporation |
Exendin fusion proteins
|
|
CN101646689A
(zh)
|
2006-09-08 |
2010-02-10 |
埃博灵克斯股份有限公司 |
具有长半衰期的血清清蛋白结合蛋白
|
|
JP2011507543A
(ja)
|
2007-12-27 |
2011-03-10 |
ノバルティス アーゲー |
改善されたフィブロネクチンベースの結合分子およびそれらの使用
|
|
PL2274331T3
(pl)
|
2008-05-02 |
2014-04-30 |
Novartis Ag |
Ulepszone cząsteczki wiążące oparte na fibronektynie i ich zastosowanie
|
|
US10233228B2
(en)
|
2010-04-09 |
2019-03-19 |
Albumedix Ltd |
Albumin derivatives and variants
|
|
EA022983B1
(ru)
|
2010-04-13 |
2016-04-29 |
Бристол-Майерс Сквибб Компани |
Белки на основе структурного домена фибронектина, связывающие pcsk9
|
|
US20140220017A1
(en)
|
2011-09-23 |
2014-08-07 |
Universitat Stuttgart |
Serum half-life extension using igbd
|
|
EP2780364A2
(en)
|
2011-11-18 |
2014-09-24 |
Eleven Biotherapeutics, Inc. |
Proteins with improved half-life and other properties
|
|
FR3009192B1
(fr)
|
2013-07-31 |
2015-09-04 |
Oreal |
Composition cosmetique anhydre comprenant de l'alkylcellulose, au moins un ester ramifie de dextrine et au moins un alcool gras
|
|
WO2016005004A1
(en)
|
2014-07-11 |
2016-01-14 |
Biontech Rna Pharmaceuticals Gmbh |
Stabilization of poly(a) sequence encoding dna sequences
|
|
US11219634B2
(en)
*
|
2015-01-21 |
2022-01-11 |
Genevant Sciences Gmbh |
Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells
|
|
US20180303925A1
(en)
|
2015-04-27 |
2018-10-25 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-Modified RNA For Inducing an Adaptive Immune Response
|
|
IL307179A
(en)
|
2015-10-28 |
2023-11-01 |
Acuitas Therapeutics Inc |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
|
BR112018069417A2
(pt)
|
2016-04-22 |
2019-01-22 |
Biontech Rna Pharmaceuticals Gmbh |
método para fornecer rna fita simples e ssrna
|
|
WO2017218704A1
(en)
*
|
2016-06-14 |
2017-12-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
|
BR112019008481A2
(pt)
*
|
2016-10-26 |
2020-03-03 |
Curevac Ag |
Vacinas de mrna de nanopartículas lipídicas
|
|
ES3063077T3
(en)
|
2016-10-26 |
2026-04-15 |
Acuitas Therapeutics Inc |
Lipid nanoparticle formulations
|